Revvity, Inc. · NYSE:RVTY

Revvity — Q3 2026 Earnings Presentation

9 slides from Revvity's earnings presentation, Nov 3, 2026

  1. Slide 1: Third Quarter 2026 Earnings

    Slide 1: Third Quarter 2026 Earnings

    Third Quarter 2026 Earnings November 3, 2026

  2. Slide 2: Safe Harbor

    Slide 2: Safe Harbor

    Safe Harbor This presentation contains "forward -looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financia

  3. Slide 3: Key Takeaways

    Slide 3: Key Takeaways

    Key Takeaways Innovation Market Performance Improving Pharma/Biotech 3Q financial performance end market conditions above expectations Launched 3 -plex solution for early detection of T1D Volume and operational AI-related demand efficiency drove meaningful Announced acquisition of continuing to buil

  4. Slide 4: 3Q26 Pro Forma Revenue Highlights

    Slide 4: 3Q26 Pro Forma Revenue Highlights

    3Q26 Pro Forma* Revenue Highlights Segments Geographic Product Mix Diagnostics Life Sciences AMERICAS APAC EU Recurring Non -recurring -LSD -LSD +MSD $0.7B +HSD +DD $0.7B +HSD $0.7B +DD *Pro Forma excludes the impact of the China Immunodiagnostics business which the Company has agreed to divest 4

  5. Slide 5: 3Q26 Financial Results

    Slide 5: 3Q26 Financial Results

    3Q26 Financial Results PRO FORMA REVENUE PRO FORMA ADJ. OP. MARGIN PRO FORMA ADJ. EPS FREE CASH FLOW $710M 29.4% $1.37 $152M +7% y/y +340bps y/y +21% y/y $451M YTD Organic: Adj. Gross Margin: Adj. Tax Rate: YTD FCF % Adj. NI: +7% | M&A: +1% | FX: -1% 62.4% | +280bps y/y 18.2% 105% Adj. Net Interest

  6. Slide 6: Life Sciences

    Slide 6: Life Sciences

    Life Sciences LIFE SCIENCES SOLUTIONS SOFTWARE PRO FORMA REVENUE ADJUSTED OP. MARGINS +DD +9% Organic Growth 31.5% Total: +11% | M&A: +2% | FX: 0 % +200bps y/y $380M 3Q26 pro forma • +LDD Pharma/Biotech & +MSD Academic/Gov’t revenue • +HSD Life Sciences Solutions, with both reagents and instruments

  7. Slide 7: Diagnostics

    Slide 7: Diagnostics

    Diagnostics IMMUNODIAGNOSTICS REPRODUCTIVE PRO FORMA REVENUE ADJUSTED OP. MARGINS HEALTH +5% Organic Growth 29.9% Total: +4% | M&A: 0% | FX: -1% +480bps y/y +LSD $330M • +HSD ImmunoDx with strength in the Americas 3Q26 pro forma +HSD revenue • +LSD Reproductive Health with +MSD growth ex -China • Si

  8. Slide 8: 2026 Pro Forma Financial Guidance

    Slide 8: 2026 Pro Forma Financial Guidance

    2026 Pro Forma* Financial Guidance REVENUE ~$2.86B Total : ~6% Organic: ~5% FX: +0.5%, M&A: +0.75 % ADJUSTED OP. MARGIN ~28.8% ADJUSTED EPS $5.40 - $5.45 Adj. net interest expense, other: ~$88M Adj. tax rate: ~18 % Average diluted share count: ~112M *Pro Forma excludes the impact of the China Immuno

  9. Slide 9: Revvity.com

    Slide 9: Revvity.com

    Revvity.com

Source: 6ix earnings call

More decks from Revvity, Inc.

All 34 Revvity decks